Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiome Expects Anti-Arrhythmic NDA Submission By 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

In a Phase III study, 52% of patients with recent onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing over Wyeth’s Cordarone and amiodarone generics, Cardiome CEO says.

You may also be interested in...



FDA Refuses To File Cardiome/Astellas RSD1235 NDA

Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.

FDA Refuses To File Cardiome/Astellas RSD1235 NDA

Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.

Cardiome Oxyprim “Approvable” For Gout, But Product’s Future Now In Doubt

FDA requests additional clinical and manufacturing data. Cardiome will “reflect” on FDA’s comments before making a final decision on oxypurinol.

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel